Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],2.11,5942,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],2.45,5943,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],9.21,5944,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],8.86,5945,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],0.67,5946,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],0.45,5947,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],6.09,5948,DB00487,Pefloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],5.83,5949,DB00487,Pefloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,3.19,5950,DB00487,Pefloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,3.55,5951,DB00487,Pefloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,15.60,5952,DB00487,Pefloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,9.45,5953,DB00487,Pefloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],3.62,5954,DB00487,Pefloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],7.39,5955,DB00487,Pefloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],137.85,5956,DB00487,Pefloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],119.8,5957,DB00487,Pefloxacin
,11711259,urinary excretion,Urinary excretion of ciprofloxacin and of ofloxacin was similar to healthy individuals but pefloxacin showed a mean urinary excretion of 30.11%.,Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),%,30.11,5958,DB00487,Pefloxacin
,8388193,maximum concentration,"After systemic administration to rabbits, the maximum concentration of sparfloxacin in serum was 5.6 micrograms.",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),μg,5.6,6938,DB00487,Pefloxacin
,8388193,half-life,ml-1 and the half-life was 7.5 h.,Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),h,7.5,6939,DB00487,Pefloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,54,6940,DB00487,Pefloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,76,6941,DB00487,Pefloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,36,6942,DB00487,Pefloxacin
,2062549,flow rates (Qdi),"Dialysate (L2D, Hospal) was circulated on the other side of the continuous venovenous hemofiltration with dialysis membrane at three different flow rates (Qdi) (0, 500 and 1,000 ml.h-1.",[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2062549/),[ml] / [h],"0, 500",7038,DB00487,Pefloxacin
,2062549,flow rates (Qdi),"Dialysate (L2D, Hospal) was circulated on the other side of the continuous venovenous hemofiltration with dialysis membrane at three different flow rates (Qdi) (0, 500 and 1,000 ml.h-1.",[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2062549/),[ml] / [h],"1,000",7039,DB00487,Pefloxacin
,2062549,sieving coefficient,Pefloxacin had a sieving coefficient of 0.42 and a clearance of 6.8 ml min-1 when Qdi was nul.,[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2062549/),,0.42,7040,DB00487,Pefloxacin
,2062549,clearance,Pefloxacin had a sieving coefficient of 0.42 and a clearance of 6.8 ml min-1 when Qdi was nul.,[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2062549/),[ml] / [min],6.8,7041,DB00487,Pefloxacin
,2062549,clearance,"With the blood flow used, clearances were found to be correlated with the dialysate flow rate; when this rate was 500 ml h-1, a pefloxacin clearance similar to that seen in healthy subjects was obtained (15.2 ml min-1).",[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2062549/),[ml] / [min],15.2,7042,DB00487,Pefloxacin
,9661000,total urinary recovery,The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),%,34,12488,DB00487,Pefloxacin
,9661000,MIC,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],0.5,12489,DB00487,Pefloxacin
,9661000,UBT,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1,12490,DB00487,Pefloxacin
,9661000,UBTs,The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1:16,12491,DB00487,Pefloxacin
,9661000,MIC,"The UBTs for Staphylococcus aureus (the MIC for which was 16 micrograms/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed.",Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],16,12492,DB00487,Pefloxacin
,7785980,maximum concentration,"Pefloxacin was found in the cornea (maximum concentration, 18.13 micrograms/ml; half-life, 3.92 h) and in the aqueous humor (maximum concentration, 3.40 micrograms/ml; half-life, 2.14 h).","Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785980/),[μg] / [ml],18.13,14180,DB00487,Pefloxacin
,7785980,half-life,"Pefloxacin was found in the cornea (maximum concentration, 18.13 micrograms/ml; half-life, 3.92 h) and in the aqueous humor (maximum concentration, 3.40 micrograms/ml; half-life, 2.14 h).","Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785980/),h,3.92,14181,DB00487,Pefloxacin
,7785980,maximum concentration,"Pefloxacin was found in the cornea (maximum concentration, 18.13 micrograms/ml; half-life, 3.92 h) and in the aqueous humor (maximum concentration, 3.40 micrograms/ml; half-life, 2.14 h).","Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785980/),[μg] / [ml],3.40,14182,DB00487,Pefloxacin
,7785980,half-life,"Pefloxacin was found in the cornea (maximum concentration, 18.13 micrograms/ml; half-life, 3.92 h) and in the aqueous humor (maximum concentration, 3.40 micrograms/ml; half-life, 2.14 h).","Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785980/),h,2.14,14183,DB00487,Pefloxacin
,12355580,MIC(90),"Most species isolated were susceptible to pefloxacin, with MIC(90) values of 0.125 microg/ml for E. coli, 0.5 microg/ml for S. epidermidis and 1 microg/ml for Cl. perfringens.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[μg] / [ml],0.125,16077,DB00487,Pefloxacin
,12355580,MIC(90),"Most species isolated were susceptible to pefloxacin, with MIC(90) values of 0.125 microg/ml for E. coli, 0.5 microg/ml for S. epidermidis and 1 microg/ml for Cl. perfringens.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[μg] / [ml],0.5,16078,DB00487,Pefloxacin
,12355580,MIC(90),"Most species isolated were susceptible to pefloxacin, with MIC(90) values of 0.125 microg/ml for E. coli, 0.5 microg/ml for S. epidermidis and 1 microg/ml for Cl. perfringens.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[μg] / [ml],1,16079,DB00487,Pefloxacin
,12355580,MIC(90),"E. faecium was resistant, with a MIC(90) value of 8 microg/ml but a MIC(50) of 4 microg/ml (intermediate).",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[μg] / [ml],8,16080,DB00487,Pefloxacin
,12355580,MIC(50),"E. faecium was resistant, with a MIC(90) value of 8 microg/ml but a MIC(50) of 4 microg/ml (intermediate).",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[μg] / [ml],4,16081,DB00487,Pefloxacin
,12355580,Elimination half-life,"Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),h,22.03,16082,DB00487,Pefloxacin
,12355580,area under the concentration-time curve from zero to infinite,"Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[h·mg] / [l],275.07,16083,DB00487,Pefloxacin
,12355580,volume of distribution at steady-state,"Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),l,96.48,16084,DB00487,Pefloxacin
,12355580,plasma clearance,"Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively.",Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355580/),[l] / [h],3.60,16085,DB00487,Pefloxacin
,3302879,serum concentration peak,The dosage of 400 mg gave a mean serum concentration peak (11.2 mg/l) and valley (5.4 mg/l) on the second day and a mean dialysate level of 5 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],11.2,18048,DB00487,Pefloxacin
,3302879,valley,The dosage of 400 mg gave a mean serum concentration peak (11.2 mg/l) and valley (5.4 mg/l) on the second day and a mean dialysate level of 5 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],5.4,18049,DB00487,Pefloxacin
,3302879,serum concentration (J14),The last mean serum concentration (J14) were 5.5 mg/l (peak) and 2.5 mg/l (valley) and the mean dialysate level was 2.6 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],5.5,18050,DB00487,Pefloxacin
,3302879,serum concentration (J14),The last mean serum concentration (J14) were 5.5 mg/l (peak) and 2.5 mg/l (valley) and the mean dialysate level was 2.6 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],2.5,18051,DB00487,Pefloxacin
,10836277,initial,"The pefloxacin was rapidly distributed from the blood to the tissue compartment as shown by the high values for the initial distribution coefficient, alpha (12.1 +/- 1.21 h-1) and the constant for the rate of transfer of drug from the central to the peripheral compartment, K12 (8.49 +/- 0.99 h ).",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),1/[h],12.1,23494,DB00487,Pefloxacin
,10836277,"distribution coefficient, alpha","The pefloxacin was rapidly distributed from the blood to the tissue compartment as shown by the high values for the initial distribution coefficient, alpha (12.1 +/- 1.21 h-1) and the constant for the rate of transfer of drug from the central to the peripheral compartment, K12 (8.49 +/- 0.99 h ).",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),1/[h],12.1,23495,DB00487,Pefloxacin
,10836277,"rate of transfer of drug from the central to the peripheral compartment, K12","The pefloxacin was rapidly distributed from the blood to the tissue compartment as shown by the high values for the initial distribution coefficient, alpha (12.1 +/- 1.21 h-1) and the constant for the rate of transfer of drug from the central to the peripheral compartment, K12 (8.49 +/- 0.99 h ).",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),h,8.49,23496,DB00487,Pefloxacin
,10836277,elimination half-life,"The elimination half-life and volume of distribution were 2.21+/- 0.111 h and 1.44 +/- 0.084 L/kg, respectively.",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),h,2.21,23497,DB00487,Pefloxacin
,10836277,volume of distribution,"The elimination half-life and volume of distribution were 2.21+/- 0.111 h and 1.44 +/- 0.084 L/kg, respectively.",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),[l] / [kg],1.44,23498,DB00487,Pefloxacin
,10836277,total body clearance (ClB),"The total body clearance (ClB) and the ratio of the drug present in the peripheral to that in the central compartment (P/C ratio) were 0.454 +/- 0.026 L/kg h) and 5.52 +/- 0.519, respectively.",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),[l] / [h·kg],0.454,23499,DB00487,Pefloxacin
,10836277,ratio of the drug,"The total body clearance (ClB) and the ratio of the drug present in the peripheral to that in the central compartment (P/C ratio) were 0.454 +/- 0.026 L/kg h) and 5.52 +/- 0.519, respectively.",Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836277/),[l] / [h·kg],0.454,23500,DB00487,Pefloxacin
,8067750,relative bioavailability,"The relative bioavailability of pefloxacin after the antacid treatment was 44.4% +/- 23.8%, compared with that after a single administration.","Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067750/),%,44.4,27423,DB00487,Pefloxacin
,2509411,Peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],14.6,36167,DB00487,Pefloxacin
,2509411,concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],13,36168,DB00487,Pefloxacin
,2509411,peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],12.3,36169,DB00487,Pefloxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],8.9,36170,DB00487,Pefloxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),,85,36171,DB00487,Pefloxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.7,36172,DB00487,Pefloxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.5,36173,DB00487,Pefloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB00487,Pefloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB00487,Pefloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB00487,Pefloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB00487,Pefloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB00487,Pefloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB00487,Pefloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB00487,Pefloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB00487,Pefloxacin
,8287635,half-life of elimination,"In the patients with liver disease, the mean (+/- SD) half-life of elimination, although highly variable, was significantly longer (46.3 +/- 42.5 hours) than in the control group (11.3 +/- 3.5 hours, p < 0.001).",Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),h,46.3,41334,DB00487,Pefloxacin
,8287635,half-life of elimination,"In the patients with liver disease, the mean (+/- SD) half-life of elimination, although highly variable, was significantly longer (46.3 +/- 42.5 hours) than in the control group (11.3 +/- 3.5 hours, p < 0.001).",Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),h,11.3,41335,DB00487,Pefloxacin
,8287635,total clearance,The total clearance was significantly decreased (1.76 +/- 1.31 L/h vs 6.03 +/- 2.99 L/h in the control group).,Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),[l] / [h],1.76,41336,DB00487,Pefloxacin
,8287635,total clearance,The total clearance was significantly decreased (1.76 +/- 1.31 L/h vs 6.03 +/- 2.99 L/h in the control group).,Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),[l] / [h],6.03,41337,DB00487,Pefloxacin
above,8287635,trough plasma concentrations,"For most patients, trough plasma concentrations were above 2 mg/L and peak plasma concentrations averaged 8.5 mg/L.",Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),[mg] / [l],2,41338,DB00487,Pefloxacin
,8287635,peak plasma concentrations,"For most patients, trough plasma concentrations were above 2 mg/L and peak plasma concentrations averaged 8.5 mg/L.",Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287635/),[mg] / [l],8.5,41339,DB00487,Pefloxacin
,3481328,peak serum concentration,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),[mg] / [l],5.5,41593,DB00487,Pefloxacin
,3481328,renal excretion during 24 hours,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),%,41,41594,DB00487,Pefloxacin
,12416870,maximum serum concentration (C0(p)),The maximum serum concentration (C0(p)) was 8.4 +/- 0.48 microg/ml; elimination half-life (t 1/2 beta) was 1.6 +/- 0.3 h; total body clearance (Cl(tot) was 3.6 +/- 0.3 L/kg/h; steady-state volume of distribution (V(dss)) was 5.14 +/- 0.21 L/kg; and the area under the curve (AUC) was 2.78 +/- 0.22 microg.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),[μg] / [ml],8.4,43096,DB00487,Pefloxacin
,12416870,elimination half-life (t 1/2 beta),The maximum serum concentration (C0(p)) was 8.4 +/- 0.48 microg/ml; elimination half-life (t 1/2 beta) was 1.6 +/- 0.3 h; total body clearance (Cl(tot) was 3.6 +/- 0.3 L/kg/h; steady-state volume of distribution (V(dss)) was 5.14 +/- 0.21 L/kg; and the area under the curve (AUC) was 2.78 +/- 0.22 microg.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),h,1.6,43097,DB00487,Pefloxacin
,12416870,total body clearance (Cl(tot),The maximum serum concentration (C0(p)) was 8.4 +/- 0.48 microg/ml; elimination half-life (t 1/2 beta) was 1.6 +/- 0.3 h; total body clearance (Cl(tot) was 3.6 +/- 0.3 L/kg/h; steady-state volume of distribution (V(dss)) was 5.14 +/- 0.21 L/kg; and the area under the curve (AUC) was 2.78 +/- 0.22 microg.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),[l] / [h·kg],3.6,43098,DB00487,Pefloxacin
,12416870,steady-state volume of distribution (V(dss)),The maximum serum concentration (C0(p)) was 8.4 +/- 0.48 microg/ml; elimination half-life (t 1/2 beta) was 1.6 +/- 0.3 h; total body clearance (Cl(tot) was 3.6 +/- 0.3 L/kg/h; steady-state volume of distribution (V(dss)) was 5.14 +/- 0.21 L/kg; and the area under the curve (AUC) was 2.78 +/- 0.22 microg.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),[l] / [kg],5.14,43099,DB00487,Pefloxacin
,12416870,area under the curve (AUC),The maximum serum concentration (C0(p)) was 8.4 +/- 0.48 microg/ml; elimination half-life (t 1/2 beta) was 1.6 +/- 0.3 h; total body clearance (Cl(tot) was 3.6 +/- 0.3 L/kg/h; steady-state volume of distribution (V(dss)) was 5.14 +/- 0.21 L/kg; and the area under the curve (AUC) was 2.78 +/- 0.22 microg.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),μg,2.78,43100,DB00487,Pefloxacin
,12416870,absorption half-life (t 1/2 ab),Pefloxacin was absorbed rapidly after i.m. injection with an absorption half-life (t 1/2 ab) of 0.32 +/- 0.02 h.,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),h,0.32,43101,DB00487,Pefloxacin
,12416870,peak serum concentration (Cmax),The peak serum concentration (Cmax) of 0.86 +/- 0.08 microg/ml was attained at 0.75 h (Tmax).,Some pharmacokinetic parameters of pefloxacin in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),[μg] / [ml],0.86,43102,DB00487,Pefloxacin
,12416870,absolute bioavailability,"The absolute bioavailability after i.m. administration was 70.63 +/- 1.13% and the serum protein-bound fraction ranged from 7.2% to 14.3%, with an average value of 9.8 +/- 1.6%.",Some pharmacokinetic parameters of pefloxacin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),%,70.63,43103,DB00487,Pefloxacin
,12416870,serum protein-bound fraction,"The absolute bioavailability after i.m. administration was 70.63 +/- 1.13% and the serum protein-bound fraction ranged from 7.2% to 14.3%, with an average value of 9.8 +/- 1.6%.",Some pharmacokinetic parameters of pefloxacin in lactating goats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),%,7.2,43104,DB00487,Pefloxacin
,12416870,serum protein-bound fraction,"The absolute bioavailability after i.m. administration was 70.63 +/- 1.13% and the serum protein-bound fraction ranged from 7.2% to 14.3%, with an average value of 9.8 +/- 1.6%.",Some pharmacokinetic parameters of pefloxacin in lactating goats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),%,14.3,43105,DB00487,Pefloxacin
,12416870,serum protein-bound fraction,"The absolute bioavailability after i.m. administration was 70.63 +/- 1.13% and the serum protein-bound fraction ranged from 7.2% to 14.3%, with an average value of 9.8 +/- 1.6%.",Some pharmacokinetic parameters of pefloxacin in lactating goats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416870/),%,9.8,43106,DB00487,Pefloxacin
,6587830,Half-lives,Half-lives ranged from 1.9 h in mice to 8.6 h in humans.,"Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),h,1.9,46778,DB00487,Pefloxacin
,6587830,Half-lives,Half-lives ranged from 1.9 h in mice to 8.6 h in humans.,"Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),h,8.6,46779,DB00487,Pefloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,0,46780,DB00487,Pefloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,1,46781,DB00487,Pefloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,1.6,46782,DB00487,Pefloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,2,46783,DB00487,Pefloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,29.5,46784,DB00487,Pefloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,37.8,46785,DB00487,Pefloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,36.3,46786,DB00487,Pefloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,26.5,46787,DB00487,Pefloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,58.9,46788,DB00487,Pefloxacin
,3480805,elimination half-life,The mean elimination half-life was significantly increased in the patients (29.0 h) compared to in 8 healthy volunteers (12.3 h).,Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),h,29.0,49933,DB00487,Pefloxacin
,3480805,elimination half-life,The mean elimination half-life was significantly increased in the patients (29.0 h) compared to in 8 healthy volunteers (12.3 h).,Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),h,12.3,49934,DB00487,Pefloxacin
,3480805,total plasma clearance,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [h],2.71,49935,DB00487,Pefloxacin
,3480805,total plasma clearance,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [h],6.85,49936,DB00487,Pefloxacin
,3480805,volume of distribution,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [kg],1.12,49937,DB00487,Pefloxacin
,3480805,volume of distribution,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [kg],1.67,49938,DB00487,Pefloxacin
,8721279,flow rate,"The drugs and the internal standard (acebutolol) were eluted from a 4-microns Novapak C-18 cartridge at ambient temperature with an isocratic mobile phase consisting of 14% acetonitrile in buffer solution, at a flow rate of 2.5 ml/min.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),[ml] / [min],2.5,57099,DB00487,Pefloxacin
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,105.5,57100,DB00487,Pefloxacin
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,99.5,57101,DB00487,Pefloxacin
,2907467,urinary,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,76.3,59596,DB00487,Pefloxacin
,2907467,fecal recoveries,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,21.0,59597,DB00487,Pefloxacin
,2907467,volume of distribution at steady state per body weight (Vdss/BW),Model-independent moment analysis of the serum concentration-time profile of [14C]NY-198 gave the volume of distribution at steady state per body weight (Vdss/BW) as 1150 ml/kg.,"Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg],1150,59598,DB00487,Pefloxacin
,2907467,Intrinsic renal clearance (CLint.kd),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],7.68,59599,DB00487,Pefloxacin
,2907467,intrinsic hepatic clearance (CLint.lv),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],6.33,59600,DB00487,Pefloxacin
,2907467,Kp,"The Kp values of NY-198 ranged from 0.22 to 4.85 and were very similar to those for ofloxacin, being the highest in the disposing organs, kidneys and liver, the lowest in fat and brain, and modest in the other nondisposing organs.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),,0.22 to 4.85,59601,DB00487,Pefloxacin
,2049424,overall elimination half-life,The overall elimination half-life was 19.9h.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),h,19.9,60566,DB00487,Pefloxacin
,2049424,bioavailability,Relative to the IV dose the bioavailability following oral administration of pefloxacin was 76%.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),%,76,60567,DB00487,Pefloxacin
,2049424,peritoneal clearance,The peritoneal clearance of pefloxacin averaged 2.5 mL/min.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),[ml] / [min],2.5,60568,DB00487,Pefloxacin
,11922483,distribution half-life (t(1/2alpha)),"Plasma pefloxacin concentrations decreased rapidly during the initial phase after i.v. injection, with a distribution half-life (t(1/2alpha)) of 0.10 +/- 0.01 h.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,0.10,64230,DB00487,Pefloxacin
,11922483,half-life (t(1/2beta)),The terminal phase had a half-life (t(1/2beta)) of 1.12 +/- 0.21 h.,Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,1.12,64231,DB00487,Pefloxacin
,11922483,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss), mean residence time (MRT) and total systemic clearance (ClB) of pefloxacin were 1.08 +/- 0.09 L/kg, 1.39 +/- 0.23 h and 821 +/- 88 (ml/h)/kg, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),[l] / [kg],1.08,64232,DB00487,Pefloxacin
,11922483,mean residence time (MRT),"The volume of distribution at steady state (Vdss), mean residence time (MRT) and total systemic clearance (ClB) of pefloxacin were 1.08 +/- 0.09 L/kg, 1.39 +/- 0.23 h and 821 +/- 88 (ml/h)/kg, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,1.39,64233,DB00487,Pefloxacin
,11922483,total systemic clearance (ClB),"The volume of distribution at steady state (Vdss), mean residence time (MRT) and total systemic clearance (ClB) of pefloxacin were 1.08 +/- 0.09 L/kg, 1.39 +/- 0.23 h and 821 +/- 88 (ml/h)/kg, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),[ml] / [h)·kg],821,64234,DB00487,Pefloxacin
,11922483,maximum concentration in the plasma (Cmax),"Following oral administration of pefloxacin, the maximum concentration in the plasma (Cmax) was 2.22 +/- 0.48 microg/ml and the interval from administration until maximum concentration (tmax) was 2.3 +/- 0.7 h.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),[μg] / [ml],2.22,64235,DB00487,Pefloxacin
,11922483,interval from administration until maximum concentration (tmax),"Following oral administration of pefloxacin, the maximum concentration in the plasma (Cmax) was 2.22 +/- 0.48 microg/ml and the interval from administration until maximum concentration (tmax) was 2.3 +/- 0.7 h.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,2.3,64236,DB00487,Pefloxacin
,11922483,absorption half-life (t(1/2ka),"The absorption half-life (t(1/2ka)) mean absorption time (MAT) and elimination half-life of pefloxacin were 0.82 +/- 0.40, 4.2 +/- 1.0 and 2.91 +/- 0.50 h, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,0.82,64237,DB00487,Pefloxacin
,11922483,mean absorption time (MAT),"The absorption half-life (t(1/2ka)) mean absorption time (MAT) and elimination half-life of pefloxacin were 0.82 +/- 0.40, 4.2 +/- 1.0 and 2.91 +/- 0.50 h, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,4.2,64238,DB00487,Pefloxacin
,11922483,elimination half-life,"The absorption half-life (t(1/2ka)) mean absorption time (MAT) and elimination half-life of pefloxacin were 0.82 +/- 0.40, 4.2 +/- 1.0 and 2.91 +/- 0.50 h, respectively.",Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),h,2.91,64239,DB00487,Pefloxacin
,11922483,oral bioavailability,The oral bioavailability of pefloxacin was 42% +/- 5.8%.,Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922483/),%,42,64240,DB00487,Pefloxacin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB00487,Pefloxacin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB00487,Pefloxacin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB00487,Pefloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB00487,Pefloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB00487,Pefloxacin
,1752112,minimum (12-hour) plasma concentration,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[mg] / [l],4.26,68292,DB00487,Pefloxacin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[mg] / [l],2.70,68293,DB00487,Pefloxacin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],78.91,68294,DB00487,Pefloxacin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],57.81,68295,DB00487,Pefloxacin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],57.81,68296,DB00487,Pefloxacin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),h,14.46,68297,DB00487,Pefloxacin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),h,10.08,68298,DB00487,Pefloxacin
,1752112,plasma clearance,"The renal clearance of pefloxacin was unchanged, but the plasma clearance increased from 94.04 +/- 39.04 to 126.82 +/- 47.36 ml/min (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[ml] / [min],94.04,68299,DB00487,Pefloxacin
,1752112,plasma clearance,"The renal clearance of pefloxacin was unchanged, but the plasma clearance increased from 94.04 +/- 39.04 to 126.82 +/- 47.36 ml/min (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[ml] / [min],126.82,68300,DB00487,Pefloxacin
,3458699,elimination (T 1/2 beta),Pefloxacin elimination (T 1/2 beta) increased from 11.00 +/- 2.64 h after the first iv dose to 13.93 +/- 3.58 h after the last iv dose (P less than 0.01).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,11.00,70526,DB00487,Pefloxacin
,3458699,elimination (T 1/2 beta),Pefloxacin elimination (T 1/2 beta) increased from 11.00 +/- 2.64 h after the first iv dose to 13.93 +/- 3.58 h after the last iv dose (P less than 0.01).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,13.93,70527,DB00487,Pefloxacin
,3458699,Apparent total body clearance,Apparent total body clearance decreased from 148.5 +/- 47.6 to 106.9 +/- 39.2 ml/min (P less than 0.01) because of decreased non-renal clearance (apparent volume of distribution did not significantly change over the repeated pefloxacin administration).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],148.5,70528,DB00487,Pefloxacin
,3458699,Apparent total body clearance,Apparent total body clearance decreased from 148.5 +/- 47.6 to 106.9 +/- 39.2 ml/min (P less than 0.01) because of decreased non-renal clearance (apparent volume of distribution did not significantly change over the repeated pefloxacin administration).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],106.9,70529,DB00487,Pefloxacin
,3458699,Renal clearance,Renal clearance of pefloxacin was low (7.47 +/- 2.28 ml/min) indicating that non-renal clearance represents the major route of elimination of this quinolone.,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],7.47,70530,DB00487,Pefloxacin
,3458699,beta-elimination half-lives,Urinary excretion of pefloxacin and N-desmethyl and N-oxide metabolites was approximately 31% of the pefloxacin dose and beta-elimination half-lives of these metabolites were very close to that of pefloxacin (13.34 +/- 2.72 h and 11.95 +/- 2.64 h respectively).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,13.34,70531,DB00487,Pefloxacin
,3458699,beta-elimination half-lives,Urinary excretion of pefloxacin and N-desmethyl and N-oxide metabolites was approximately 31% of the pefloxacin dose and beta-elimination half-lives of these metabolites were very close to that of pefloxacin (13.34 +/- 2.72 h and 11.95 +/- 2.64 h respectively).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,11.95,70532,DB00487,Pefloxacin
,3458699,accumulation ratio,"Due to a possible saturable process in the metabolic pathway, some accumulation occurred during repeated iv or oral treatment (accumulation ratio = 1.37 +/- 0.20).",Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),,1.37,70533,DB00487,Pefloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.2,77966,DB00487,Pefloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.9,77967,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.75,77968,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.9,77969,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,4.0,77970,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,7.0,77971,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,6.2,77972,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,5.1,77973,DB00487,Pefloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,10.5,77974,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,62,77975,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,46.4,77976,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,12.2,77977,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,27,77978,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,30.6,77979,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,75.7,77980,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,73,77981,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,4.9,77982,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,9.2,77983,DB00487,Pefloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,17.8,77984,DB00487,Pefloxacin
,7666121,peak,"Ciprofloxacin, having a shorter half-life, showed a peak of about 1 microgram/ml, 12 hours after administration (500 mg/12 hours/os).",Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666121/),[μg] / [ml],1,79970,DB00487,Pefloxacin
,3862496,t1/2,"In the patients with cirrhosis, the mean (+/- SD) t1/2, although highly variable, was significantly longer (35.10 +/- 19.00 hours) than in the normal subjects (11.00 +/- 2.64 hours; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),h,35.10,79995,DB00487,Pefloxacin
,3862496,t1/2,"In the patients with cirrhosis, the mean (+/- SD) t1/2, although highly variable, was significantly longer (35.10 +/- 19.00 hours) than in the normal subjects (11.00 +/- 2.64 hours; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),h,11.00,79996,DB00487,Pefloxacin
,3862496,total plasma clearance,"In the patients, the volume of distribution was decreased by 18% (P less than 0.02) and total plasma clearance was markedly decreased (2.66 +/- 1.85 vs. 8.19 +/- 2.80 L/hr X 1.73 m2; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),[l] / [1.73·h·m2],2.66,79997,DB00487,Pefloxacin
,3862496,total plasma clearance,"In the patients, the volume of distribution was decreased by 18% (P less than 0.02) and total plasma clearance was markedly decreased (2.66 +/- 1.85 vs. 8.19 +/- 2.80 L/hr X 1.73 m2; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),[l] / [1.73·h·m2],8.19,79998,DB00487,Pefloxacin
,1302767,CL,"Predicted PF CL for a patient with median covariates values was similar in both BE/MLR and NONMEM analysis (4.02 and 3.92 L/hr, respectively).",Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302767/),[l] / [h],4.02,82274,DB00487,Pefloxacin
,1302767,CL,"Predicted PF CL for a patient with median covariates values was similar in both BE/MLR and NONMEM analysis (4.02 and 3.92 L/hr, respectively).",Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302767/),[l] / [h],3.92,82275,DB00487,Pefloxacin
,3549940,peak serum concentration,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],3.6,82726,DB00487,Pefloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],9.2,82727,DB00487,Pefloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],16.9,82728,DB00487,Pefloxacin
,3549940,half-lives for serum elimination,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),h,2,82729,DB00487,Pefloxacin
,3481335,peak serum level,The mean peak serum level of 6.6 micrograms/ml was attained rapidly 0.8 h after administration.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),[μg] / [ml],6.6,85017,DB00487,Pefloxacin
,3481335,serum elimination half-life,The mean serum elimination half-life was 11.6 h.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),h,11.6,85018,DB00487,Pefloxacin
,3481335,peak level,Inflammatory fluid was penetrated quickly with a mean peak level of 3.9 micrograms/ml occurring at 2.4 h.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),[μg] / [ml],3.9,85019,DB00487,Pefloxacin
,3481335,24 h,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,8.0,85020,DB00487,Pefloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,8.0,85021,DB00487,Pefloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,12.0,85022,DB00487,Pefloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,13.1,85023,DB00487,Pefloxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,0.9,86368,DB00487,Pefloxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,1.3,86369,DB00487,Pefloxacin
,3141343,plasma elimination half-life,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),,11.9,86370,DB00487,Pefloxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],5.62,86371,DB00487,Pefloxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],4.09,86372,DB00487,Pefloxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],65.9,86373,DB00487,Pefloxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],48.7,86374,DB00487,Pefloxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],70.7,86375,DB00487,Pefloxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],51.5,86376,DB00487,Pefloxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],51.8,86377,DB00487,Pefloxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],11.7,86378,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,48.6,86379,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,8.6,86380,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,7.1,86381,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,17.4,86382,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,3.8,86383,DB00487,Pefloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,16.6,86384,DB00487,Pefloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.53,99479,DB00487,Pefloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.34,99480,DB00487,Pefloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0. 43,99481,DB00487,Pefloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.39,99482,DB00487,Pefloxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],0.1,101755,DB00487,Pefloxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],1,101756,DB00487,Pefloxacin
,3480804,minimal,"On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg.l-1 respectively, after oral administration.",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],5.9,112585,DB00487,Pefloxacin
,3480804,maximal plasma concentrations,"On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg.l-1 respectively, after oral administration.",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],11.5,112586,DB00487,Pefloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],0.9,112587,DB00487,Pefloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],1.2,112588,DB00487,Pefloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],6.2,112589,DB00487,Pefloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],9.0,112590,DB00487,Pefloxacin
,12816179,MIC90,"These values were above the MIC90 for E. coli (0.125 microg/ml) and E. faecalis (0.5 microg/ml), microorganisms responsible for abdominal infections.",Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),[μg] / [ml],0.125,112880,DB00487,Pefloxacin
,12816179,MIC90,"These values were above the MIC90 for E. coli (0.125 microg/ml) and E. faecalis (0.5 microg/ml), microorganisms responsible for abdominal infections.",Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),[μg] / [ml],0.5,112881,DB00487,Pefloxacin
,12816179,plasma concentrations,Mean plasma concentrations of metronidazole decreased from 39.89 +/- 17.08 microg/ml at the end of the infusion to 2.63 +/- 1.11 microg/ml at 36 h.,Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),[μg] / [ml],39.89,112882,DB00487,Pefloxacin
,12816179,plasma concentrations,Mean plasma concentrations of metronidazole decreased from 39.89 +/- 17.08 microg/ml at the end of the infusion to 2.63 +/- 1.11 microg/ml at 36 h.,Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),[μg] / [ml],2.63,112883,DB00487,Pefloxacin
,12816179,AUC/MIC,"The AUC/MIC values (efficacy parameter for concentration-dependent killing antibiotics such as pefloxacin and metronidazole) obtained were the following: metronidazole AUC/MIC value for B. fragilis was 173; pefloxacin AUC/MIC values for E. coli and E. faecalis were 941 and 235, respectively.",Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),,173,112884,DB00487,Pefloxacin
,12816179,AUC/MIC,"The AUC/MIC values (efficacy parameter for concentration-dependent killing antibiotics such as pefloxacin and metronidazole) obtained were the following: metronidazole AUC/MIC value for B. fragilis was 173; pefloxacin AUC/MIC values for E. coli and E. faecalis were 941 and 235, respectively.",Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),,941,112885,DB00487,Pefloxacin
,12816179,AUC/MIC,"The AUC/MIC values (efficacy parameter for concentration-dependent killing antibiotics such as pefloxacin and metronidazole) obtained were the following: metronidazole AUC/MIC value for B. fragilis was 173; pefloxacin AUC/MIC values for E. coli and E. faecalis were 941 and 235, respectively.",Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12816179/),,235,112886,DB00487,Pefloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],23.0,113561,DB00487,Pefloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],14.4,113562,DB00487,Pefloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.2,113963,DB00487,Pefloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.9,113964,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.75,113965,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.9,113966,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,4.0,113967,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,7.0,113968,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,6.2,113969,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,5.1,113970,DB00487,Pefloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,10.5,113971,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113972,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113973,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113974,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113975,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113976,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113977,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113978,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113979,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113980,DB00487,Pefloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113981,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113982,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113983,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113984,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113985,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113986,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113987,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113988,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113989,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113990,DB00487,Pefloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113991,DB00487,Pefloxacin
,2933340,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.03 and 4,121285,DB00487,Pefloxacin
,2933340,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except for two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.25 and 16,121286,DB00487,Pefloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.7 and 6.3,121287,DB00487,Pefloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],3.6,121288,DB00487,Pefloxacin
,2933340,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),%,31.2,121289,DB00487,Pefloxacin
,3054753,critical concentration,"Up until the 24th hour, in 25/26 cases, the bone levels were superior to 2 mg/l (the critical concentration of pefloxacin) in cortical as well as in spongy bone.",[Kinetics of pefloxacin diffusion in human bone tissue following a single infusion of 800 mg. Evaluation of an extraction technic using chloroform]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054753/),[mg] / [l],2,124098,DB00487,Pefloxacin
,11250882,brain-to-blood coefficient of distribution,"2. Following pefloxacin administration, the brain-to-blood coefficient of distribution was 0.036.","Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250882/),,0.036,125115,DB00487,Pefloxacin
,11250882,coefficient of distribution (k,The bile-to-blood coefficient of distribution (k=AUC(bile)/AUC(blood)) was 1.53.,"Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250882/),,1.53,125116,DB00487,Pefloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB00487,Pefloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB00487,Pefloxacin
,3459221,apparent volume of distribution (AVD,The high apparent volume of distribution (AVD = 117 +/- 6 litres) reflects good diffusion in extravascular compartments.,[Pharmacokinetic behavior of pefloxacin in man]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),l,117,128222,DB00487,Pefloxacin
,3459221,elimination half-life,"In subjects with normal liver function, the mean elimination half-life is almost 12 h, which makes it possible to administer pefloxacin twice a day.",[Pharmacokinetic behavior of pefloxacin in man]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),h,12,128223,DB00487,Pefloxacin
,3459221,peak plasma concentrations,"During treatment with 400 mg doses, the steady state is reached within 48 h; mean peak plasma concentrations then are 10 micrograms X ml-1 and mean trough concentrations 4 micrograms X ml-1.",[Pharmacokinetic behavior of pefloxacin in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),[μg] / [ml],10,128224,DB00487,Pefloxacin
,3459221,trough concentrations,"During treatment with 400 mg doses, the steady state is reached within 48 h; mean peak plasma concentrations then are 10 micrograms X ml-1 and mean trough concentrations 4 micrograms X ml-1.",[Pharmacokinetic behavior of pefloxacin in man]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),[μg] / [ml],4,128225,DB00487,Pefloxacin
,12541603,flow rate,The flow rate was 1.2 mL/min and the monitoring wavelength was 295 nm.,[Determination of rufloxacin in human plasma by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12541603/),[ml] / [min],1.2,142555,DB00487,Pefloxacin
,12541603,detection limit,The detection limit of rufloxacin was 0.05 mg/L for plasma and the recovery was (97.7 +/- 2.1)%.,[Determination of rufloxacin in human plasma by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12541603/),[mg] / [l],0.05,142556,DB00487,Pefloxacin
,12541603,recovery,The detection limit of rufloxacin was 0.05 mg/L for plasma and the recovery was (97.7 +/- 2.1)%.,[Determination of rufloxacin in human plasma by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12541603/),%,97.7,142557,DB00487,Pefloxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,5.2,154619,DB00487,Pefloxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,6.8,154620,DB00487,Pefloxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,12,154621,DB00487,Pefloxacin
,9691332,percent recovery,The percent recovery from the nominal values for accuracy ranged from 94 to 108%.,Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,94 to 108,154622,DB00487,Pefloxacin
,9691332,detection limits,"The detection limits were 10 ng/ml and 25 ng/g, respectively.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),[ng] / [ml],10,154623,DB00487,Pefloxacin
,9691332,detection limits,"The detection limits were 10 ng/ml and 25 ng/g, respectively.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),[ng] / [g],25,154624,DB00487,Pefloxacin
,9691332,extraction recoveries,"In plasma, the extraction recoveries averaged 52% for enoxacin and 63% for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,52,154625,DB00487,Pefloxacin
,9691332,extraction recoveries,"In plasma, the extraction recoveries averaged 52% for enoxacin and 63% for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,63,154626,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB00487,Pefloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB00487,Pefloxacin
,19576860,detection limit,"Under optimised conditions, the calibration curve was linear from 0.02 to 12 mg/L with a detection limit of 0.004 mg/L (sigma=3).",Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576860/),[mg] / [l],0.004,159063,DB00487,Pefloxacin
,19576860,recoveries,The recoveries in human urine were 96.2% to 98.3%.,Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576860/),%,96.2,159064,DB00487,Pefloxacin
,19576860,recoveries,The recoveries in human urine were 96.2% to 98.3%.,Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576860/),%,98.3,159065,DB00487,Pefloxacin
,19576860,urinary excretion ratio,The urinary excretion ratio of PM was 13.6% within 48 h.,Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576860/),%,13.6,159066,DB00487,Pefloxacin
,3463543,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.03 and 4,159866,DB00487,Pefloxacin
,3463543,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.25 and 16,159867,DB00487,Pefloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.7 and 6.3,159868,DB00487,Pefloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],3.6,159869,DB00487,Pefloxacin
,3463543,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),%,31.2,159870,DB00487,Pefloxacin
,1820906,t1/2,"Pharmacokinetic parameters (and their inter-individual variability) in patients differed significantly from those of healthy volunteers (e.g. t1/2 of 22 +/- 14 h, range 6-81 h vs. 11 +/- 2 h, range 8-17, p less than 0.001).",Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820906/),h,22,160692,DB00487,Pefloxacin
,1820906,t1/2,"Pharmacokinetic parameters (and their inter-individual variability) in patients differed significantly from those of healthy volunteers (e.g. t1/2 of 22 +/- 14 h, range 6-81 h vs. 11 +/- 2 h, range 8-17, p less than 0.001).",Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820906/),h,11,160693,DB00487,Pefloxacin
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.4,161347,DB00487,Pefloxacin
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.5,161348,DB00487,Pefloxacin
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161349,DB00487,Pefloxacin
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],4.9,161350,DB00487,Pefloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.13,161351,DB00487,Pefloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161352,DB00487,Pefloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.53,161353,DB00487,Pefloxacin
,2338418,peak concentration,The mean peak concentration in pancreatic juice was 4.6 +/- 0.9 mg/l (+/- S.E.) and occurred at 2.5 h after drug intake.,Penetration of pefloxacin into human allograft pancreatic juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338418/),[mg] / [l],4.6,162638,DB00487,Pefloxacin
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB00487,Pefloxacin
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB00487,Pefloxacin
,1624396,elimination half-life,"The mean elimination half-life of pefloxacin was 11.3 h, the mean residence time (MRT) was 15.8 h and the apparent volume of distribution 1.52 +/- 0.525 L/kg.",Penetration of pefloxacin into gynaecological tissues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1624396/),h,11.3,172517,DB00487,Pefloxacin
,1624396,mean residence time (MRT),"The mean elimination half-life of pefloxacin was 11.3 h, the mean residence time (MRT) was 15.8 h and the apparent volume of distribution 1.52 +/- 0.525 L/kg.",Penetration of pefloxacin into gynaecological tissues. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1624396/),h,15.8,172518,DB00487,Pefloxacin
,1624396,apparent volume of distribution,"The mean elimination half-life of pefloxacin was 11.3 h, the mean residence time (MRT) was 15.8 h and the apparent volume of distribution 1.52 +/- 0.525 L/kg.",Penetration of pefloxacin into gynaecological tissues. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1624396/),[l] / [kg],1.52,172519,DB00487,Pefloxacin
,1624396,skin/plasma concentration ratio,"At the start of surgery, about 2.5 h after the last dose, the skin/plasma concentration ratio and the peritoneum/plasma concentration ratio were 2.65 and 1.18, respectively.",Penetration of pefloxacin into gynaecological tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1624396/),,2.65,172520,DB00487,Pefloxacin
,1624396,peritoneum/plasma concentration ratio,"At the start of surgery, about 2.5 h after the last dose, the skin/plasma concentration ratio and the peritoneum/plasma concentration ratio were 2.65 and 1.18, respectively.",Penetration of pefloxacin into gynaecological tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1624396/),,1.18,172521,DB00487,Pefloxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],77.8,180503,DB00487,Pefloxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],31.8,180504,DB00487,Pefloxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,9.7,180505,DB00487,Pefloxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,4.5,180506,DB00487,Pefloxacin
,8182004,half-life,The vitreal half-life was short (3 h).,Kinetics and tolerability of intravitreal pefloxacin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8182004/),h,3,181855,DB00487,Pefloxacin
,8182004,maximum non-toxic dosage,"Toxicity studies, including ophthalmological and histopathological investigations, identified a maximum non-toxic dosage of 400 micrograms.",Kinetics and tolerability of intravitreal pefloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8182004/),μg,400,181856,DB00487,Pefloxacin
,18296885,MIC,"Based on the MIC of 0.8 microg/ml of pefloxacin, a priming dose of 6.0 mg/kg and a maintenance dose of 2.21 mg/kg is required to be administered at 8 h intervals.",Effect of trikatu pretreatment on the pharmacokinetics of pefloxacin administered orally in mountain Gaddi goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296885/),[μg] / [ml],0.8,182654,DB00487,Pefloxacin
,1864290,penetration,"The penetration of ciprofloxacin into the vitreous humor, based primarily on the data from one report, is about 20%.",Use of quinolones for treatment of ear and eye infections. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864290/),%,20,188476,DB00487,Pefloxacin
,6594505,half-lives,"After intravenous infusion, the pharmacokinetic profiles of the plasma concentrations showed a biphasic decline, with half-lives (mean +/- SD) of 8.55 +/- 4.20 min and 11.50 +/- 1.75 h, respectively.","Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594505/),min,8.55,189179,DB00487,Pefloxacin
,6594505,half-lives,"After intravenous infusion, the pharmacokinetic profiles of the plasma concentrations showed a biphasic decline, with half-lives (mean +/- SD) of 8.55 +/- 4.20 min and 11.50 +/- 1.75 h, respectively.","Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594505/),h,11.50,189180,DB00487,Pefloxacin
,16446993,elimination half-life (t(1/2beta)),"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),h,8.46,191413,DB00487,Pefloxacin
,16446993,area under the plasma concentration-time curve (AUC),"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[h·μg] / [ml],39.06,191414,DB00487,Pefloxacin
,16446993,area under the plasma concentration-time curve (AUC),"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[μg] / [ml],2.69,191415,DB00487,Pefloxacin
,16446993,maximum plasma drug concentration (C(max)),"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[h·μg] / [ml],39.06,191416,DB00487,Pefloxacin
,16446993,mean residence time (MRT),"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[h·μg] / [ml],39.06,191417,DB00487,Pefloxacin
,16446993,bioavailability,"In the birds not exposed to arsenic and/or malathion, the elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), maximum plasma drug concentration (C(max)), mean residence time (MRT), and bioavailability of pefloxacin were 8.46 +/- 0.24 h, 39.06 +/- 1.13 microg.h.ml(-1), 2.69 +/- 0.19 microg.ml(-1), 12.29 +/- 0.48 h, and 60.52 +/- 1.74%, respectively.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),%,60.52,191418,DB00487,Pefloxacin
,16446993,C(max),Exposure to arsenic was associated with a significant increase in C(max) (4.28 +/- 0.45 microg.ml(-1)) and a nonsignificant increase in the values of AUC (48.96 +/- 2.55 microg.h.ml(-1)) and bioavailability (74.55 +/- 3.8 %) of pefloxacin.,Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[μg] / [ml],4.28,191419,DB00487,Pefloxacin
,16446993,AUC,Exposure to arsenic was associated with a significant increase in C(max) (4.28 +/- 0.45 microg.ml(-1)) and a nonsignificant increase in the values of AUC (48.96 +/- 2.55 microg.h.ml(-1)) and bioavailability (74.55 +/- 3.8 %) of pefloxacin.,Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[h·μg] / [ml],48.96,191420,DB00487,Pefloxacin
,16446993,bioavailability,Exposure to arsenic was associated with a significant increase in C(max) (4.28 +/- 0.45 microg.ml(-1)) and a nonsignificant increase in the values of AUC (48.96 +/- 2.55 microg.h.ml(-1)) and bioavailability (74.55 +/- 3.8 %) of pefloxacin.,Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),%,74.55,191421,DB00487,Pefloxacin
,16446993,AUC,"The values of AUC (51.62 +/- 4.76 microg.h.ml(-1)), t(1/2beta) (12.57 +/- 1.26 h), MRT (19.94 +/- 1.99 h), and bioavailability (78.59 +/- 7.25 %) of pefloxacin were significantly increased in malathion-exposed birds.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),[h·μg] / [ml],51.62,191422,DB00487,Pefloxacin
,16446993,t(1/2beta),"The values of AUC (51.62 +/- 4.76 microg.h.ml(-1)), t(1/2beta) (12.57 +/- 1.26 h), MRT (19.94 +/- 1.99 h), and bioavailability (78.59 +/- 7.25 %) of pefloxacin were significantly increased in malathion-exposed birds.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),h,12.57,191423,DB00487,Pefloxacin
,16446993,MRT,"The values of AUC (51.62 +/- 4.76 microg.h.ml(-1)), t(1/2beta) (12.57 +/- 1.26 h), MRT (19.94 +/- 1.99 h), and bioavailability (78.59 +/- 7.25 %) of pefloxacin were significantly increased in malathion-exposed birds.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),h,19.94,191424,DB00487,Pefloxacin
,16446993,bioavailability,"The values of AUC (51.62 +/- 4.76 microg.h.ml(-1)), t(1/2beta) (12.57 +/- 1.26 h), MRT (19.94 +/- 1.99 h), and bioavailability (78.59 +/- 7.25 %) of pefloxacin were significantly increased in malathion-exposed birds.",Interactive alterations of arsenic and malathion in the disposition kinetics of pefloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446993/),%,78.59,191425,DB00487,Pefloxacin
,28596959,elimination half-life (t½β),"For pefloxacin, the elimination half-life (t½β) was 8.44 ± 0.48 and 13.18 ± 0.82 h after IV and oral administration, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,8.44,193133,DB00487,Pefloxacin
,28596959,elimination half-life (t½β),"For pefloxacin, the elimination half-life (t½β) was 8.44 ± 0.48 and 13.18 ± 0.82 h after IV and oral administration, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,13.18,193134,DB00487,Pefloxacin
,28596959,absorption half-life (t½a),"After single oral dose, pefloxacin was rapidly absorbed with an absorption half-life (t½a) and TMAX of 0.87 ± 0.07 and 2.01 ± 0.12 h, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,0.87,193135,DB00487,Pefloxacin
,28596959,TMAX,"After single oral dose, pefloxacin was rapidly absorbed with an absorption half-life (t½a) and TMAX of 0.87 ± 0.07 and 2.01 ± 0.12 h, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,2.01,193136,DB00487,Pefloxacin
,28596959,Maximum plasma concentration (CMAX),Maximum plasma concentration (CMAX) was 4.02 ± 0.31 µg/mL.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),[μg] / [ml],4.02,193137,DB00487,Pefloxacin
,28596959,Oral bioavailability,Oral bioavailability of pefloxacin was found to be 70 ± 2%.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),%,70,193138,DB00487,Pefloxacin
,28596959,maximal plasma concentration (CMAX),The maximal plasma concentration (CMAX) of N-demethyl pefloxacin (norfloxacin) was calculated as 0.19 ± 0.01 mg/mL.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),[mg] / [ml],0.19,193139,DB00487,Pefloxacin
,28596959,t½β,The t½β of N-demethyl pefloxacin after oral pefloxacin administration was 10.93 ± 0.80 h.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,10.93,193140,DB00487,Pefloxacin
,7882634,elimination half-life,Its elimination half-life ranges from 6.2 to 12.4 hours.,Pefloxacin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7882634/),h,6.2 to 12.4,193898,DB00487,Pefloxacin
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB00487,Pefloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB00487,Pefloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB00487,Pefloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB00487,Pefloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB00487,Pefloxacin
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB00487,Pefloxacin
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB00487,Pefloxacin
,9323468,steady-state concentration,"Fosfomycin was administered as a continuous infusion at a constant flow, allowing a steady-state concentration of 47.4 +/- 11.9 mg/ml to be reached in serum.",Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9323468/),[mg] / [ml],47.4,203646,DB00487,Pefloxacin
,11282268,central,The central and peripheral concentrations were similar and had a mean value of 4.39 microg/g of tissue.,Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11282268/),[μg] / [g],4.39,224816,DB00487,Pefloxacin
,1929314,half-life,"In this study, the half-life of the drug was 18.8 +/- 1.4 h, i.e., apparently longer than that reported for normal controls or uremic patients on hemodialysis.","Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929314/),h,18.8,226639,DB00487,Pefloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of amikacin were 27.3 and 3.3 mg/l.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],27.3,238442,DB00487,Pefloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of amikacin were 27.3 and 3.3 mg/l.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],3.3,238443,DB00487,Pefloxacin
,3169115,total plasma clearance,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],83.1,238444,DB00487,Pefloxacin
,3169115,total plasma clearance,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],67.0,238445,DB00487,Pefloxacin
,3169115,half-life,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,3.9,238446,DB00487,Pefloxacin
,3169115,half-life,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,5.0,238447,DB00487,Pefloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],13.1,238448,DB00487,Pefloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],13.4,238449,DB00487,Pefloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],7.9,238450,DB00487,Pefloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],9.0,238451,DB00487,Pefloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,11.3,238452,DB00487,Pefloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,19.4,238453,DB00487,Pefloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,21.1,238454,DB00487,Pefloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],90.8,238455,DB00487,Pefloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],51.9,238456,DB00487,Pefloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],56.4,238457,DB00487,Pefloxacin
,3169115,steady-state plasma concentrations,Mean steady-state plasma concentrations of norfloxacin and pefloxacin N-oxide were respectively 0.5-0.6 mg/l and 0.9-1.3 mg/l after intravenous and oral administration of pefloxacin.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],0.5-0.6,238458,DB00487,Pefloxacin
,3169115,steady-state plasma concentrations,Mean steady-state plasma concentrations of norfloxacin and pefloxacin N-oxide were respectively 0.5-0.6 mg/l and 0.9-1.3 mg/l after intravenous and oral administration of pefloxacin.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],0.9-1.3,238459,DB00487,Pefloxacin
,16359117,limit of detection,The limit of detection for pefloxacin and norfloxacin was 0.03 microg/ml in plasma or microg/g in tissue.,Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],0.03,239906,DB00487,Pefloxacin
,16359117,elimination half-life,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,8.74,239907,DB00487,Pefloxacin
,16359117,time to reach maximum plasma drug concentration,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],3.78,239908,DB00487,Pefloxacin
,16359117,time to reach maximum plasma drug concentration,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,3.33,239909,DB00487,Pefloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,14.32,239910,DB00487,Pefloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,5.66,239911,DB00487,Pefloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],0.80,239912,DB00487,Pefloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,3.67,239913,DB00487,Pefloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,14.44,239914,DB00487,Pefloxacin
,2731058,plasma levels,The pefloxacin given orally was found to achieve satisfactory plasma levels of 5.4 to 6.9 mg.l-1 during sternotomy and always higher than 3 mg.l-1 during bypass.,[Antibiotic prophylaxis using a combination of pefloxacin and fosfomycin in heart surgery with CEC (extracorporeal circulation) in patients allergic to beta-lactams]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731058/),[mg] / [l],5.4 to 6.9,252635,DB00487,Pefloxacin
,2731058,residual plasma level,"At the sternal closure, the residual plasma level was about 2.8 mg.l-1 before the reinfusion.",[Antibiotic prophylaxis using a combination of pefloxacin and fosfomycin in heart surgery with CEC (extracorporeal circulation) in patients allergic to beta-lactams]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731058/),[mg] / [l],2.8,252636,DB00487,Pefloxacin
,21783705,elimination half-life (t(1/2β)),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),h,8.2,253339,DB00487,Pefloxacin
,21783705,area under the plasma concentration-time curve (AUC),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),1/[μghml],66,253340,DB00487,Pefloxacin
,21783705,area under the plasma concentration-time curve (AUC),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),1/[μghml],31,253341,DB00487,Pefloxacin
,21783705,mean residence time (MRT),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),h,10.5,253342,DB00487,Pefloxacin
,21783705,mean residence time (MRT),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),1/[μghml],31,253343,DB00487,Pefloxacin
,21783705,mean residence time (MRT),"Following intravenous administration of pefloxacin, elimination half-life (t(1/2β)), area under the plasma concentration-time curve (AUC) and mean residence time (MRT) were 8.2±0.7h, 66±9μghml(-1) and 10.5±1.1h, respectively, and when the drug was administered orally, the respective values of pharmacokinetic parameters were 8.2±0.4h, 31±3.1μghml(-1) and 11.7±0.6h.",Effects of subchronic malathion exposure on the pharmacokinetic disposition of pefloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783705/),h,11.7,253344,DB00487,Pefloxacin
,8494368,areas under the concentration-versus-time curve,The mean areas under the concentration-versus-time curve for plasma were not different (138 versus 136 h.mg/liter).,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[h·mg] / [l],138,253748,DB00487,Pefloxacin
,8494368,areas under the concentration-versus-time curve,The mean areas under the concentration-versus-time curve for plasma were not different (138 versus 136 h.mg/liter).,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[h·mg] / [l],136,253749,DB00487,Pefloxacin
,8494368,maximal concentration,The mean (+/- standard deviation) maximal concentration after the 800-mg infusion was 12.11 +/- 1.35 versus 6.51 +/- 0.73 mg/liter after the first 400-mg infusion and 7.42 +/- 0.76 mg/liter after the second 400-mg infusion.,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[mg] / [l],12.11,253750,DB00487,Pefloxacin
,8494368,maximal concentration,The mean (+/- standard deviation) maximal concentration after the 800-mg infusion was 12.11 +/- 1.35 versus 6.51 +/- 0.73 mg/liter after the first 400-mg infusion and 7.42 +/- 0.76 mg/liter after the second 400-mg infusion.,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[mg] / [l],6.51,253751,DB00487,Pefloxacin
,8494368,maximal concentration,The mean (+/- standard deviation) maximal concentration after the 800-mg infusion was 12.11 +/- 1.35 versus 6.51 +/- 0.73 mg/liter after the first 400-mg infusion and 7.42 +/- 0.76 mg/liter after the second 400-mg infusion.,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[mg] / [l],7.42,253752,DB00487,Pefloxacin
,8494368,trough concentrations,Mean trough concentrations at 24 h were significantly different: 2.77 +/- 0.63 (800 mg) versus 1.93 +/- 0.49 (400 mg twice) mg/liter (P = 0.0007).,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[mg] / [l],2.77,253753,DB00487,Pefloxacin
,8494368,trough concentrations,Mean trough concentrations at 24 h were significantly different: 2.77 +/- 0.63 (800 mg) versus 1.93 +/- 0.49 (400 mg twice) mg/liter (P = 0.0007).,Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),[mg] / [l],1.93,253754,DB00487,Pefloxacin
higher,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),-1,1,253755,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,1,253756,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),-1,1,253757,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,12,253758,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),,1,253759,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,24,253760,DB00487,Pefloxacin
higher,8494368,SBAs,"Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),,1/64,253761,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,1,253762,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),,1,253763,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,12,253764,DB00487,Pefloxacin
,8494368,SBAs,"Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h).",Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494368/),h,24,253765,DB00487,Pefloxacin
,24577931,retention time,"The retention time for pefloxacin 18±1 min and paracetamol were approximately 6±1 min, respectively.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),min,18,254395,DB00487,Pefloxacin
,24577931,retention time,"The retention time for pefloxacin 18±1 min and paracetamol were approximately 6±1 min, respectively.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),min,6,254396,DB00487,Pefloxacin
,24577931,AUC0-∞,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[h·μg] / [ml],67.355,254397,DB00487,Pefloxacin
,24577931,AUC0-∞,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[h·μg] / [ml],61.242,254398,DB00487,Pefloxacin
,24577931,relative bioavailability,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),,91.395,254399,DB00487,Pefloxacin
,24577931,maximum plasma concentrations,Under the control and treatment condition the mean maximum plasma concentrations were found to be 4.679±0.248 μg/ml and 4.6595±0.266 μg/ml respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[μg] / [ml],4.679,254400,DB00487,Pefloxacin
,24577931,maximum plasma concentrations,Under the control and treatment condition the mean maximum plasma concentrations were found to be 4.679±0.248 μg/ml and 4.6595±0.266 μg/ml respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[μg] / [ml],4.6595,254401,DB00487,Pefloxacin
,24577931,T(max),The average T(max) for plasma concentrations was 1.819±0.1743hr and 1.605 ±0.1134hr respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,1.819,254402,DB00487,Pefloxacin
,24577931,T(max),The average T(max) for plasma concentrations was 1.819±0.1743hr and 1.605 ±0.1134hr respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,1.605,254403,DB00487,Pefloxacin
,24577931,biological half-lives,The biological half-lives in the two phases of studies were found to be 7.953±0.33hr in control and 7.7257±0.355hr in treatment.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,7.953,254404,DB00487,Pefloxacin
,24577931,biological half-lives,The biological half-lives in the two phases of studies were found to be 7.953±0.33hr in control and 7.7257±0.355hr in treatment.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,7.7257,254405,DB00487,Pefloxacin
,3865778,volume of distribution (Vd area),"The mean volume of distribution (Vd area) and the mean plasma clearance were 2.03 l X kg-1 and 121.3 ml X min-1, respectively.",Pharmacokinetics of pefloxacin in renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),[l] / [kg],2.03,257172,DB00487,Pefloxacin
,3865778,plasma clearance,"The mean volume of distribution (Vd area) and the mean plasma clearance were 2.03 l X kg-1 and 121.3 ml X min-1, respectively.",Pharmacokinetics of pefloxacin in renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),[ml] / [min],121.3,257173,DB00487,Pefloxacin
,3865778,apparent elimination half-life,The mean apparent elimination half-life was 13.5 h.,Pharmacokinetics of pefloxacin in renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),h,13.5,257174,DB00487,Pefloxacin
greater,3297363,volume of distribution,"Some common pharmacokinetic parameters: low protein binding (less than 50%); high volume of distribution (greater than 1.5 l/kg) with good attainable tissue concentrations in lymph, blister fluid, renal tissue, prostate, bronchial secretions, saliva, aqueous humor, CSF, bone, bile; good intracellular penetration in macrophages, polynuclear neutrophils; high peak urinary concentrations markedly exceeding the MIC for virtually all bacterial urinary tract pathogens, even accounting for the increase in MIC in the urine, especially at lower (acidic) pH; low extraction ratio dialysis; similar adverse reactions; CNS, gastro-intestinal, photosensitivity, tendo-articular and cartilage toxicity.",Comparative pharmacokinetic parameters of new systemic fluoroquinolones: a review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297363/),[l] / [kg],1.5,258450,DB00487,Pefloxacin
,2080483,Total body clearance,"Total body clearance was decreased (0.66 +/- 0.16 ml/min/kg) and elimination half life was increased as compared to that observed in normal subject (28.2 +/- 7.6 h), the longest half-lives being observed in the cases with the most severe alteration of hepatic function.",[Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080483/),[ml] / [kg·min],0.66,261546,DB00487,Pefloxacin
,2080483,elimination half life,"Total body clearance was decreased (0.66 +/- 0.16 ml/min/kg) and elimination half life was increased as compared to that observed in normal subject (28.2 +/- 7.6 h), the longest half-lives being observed in the cases with the most severe alteration of hepatic function.",[Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080483/),h,28.2,261547,DB00487,Pefloxacin
higher,2080483,Peritoneal concentrations,Peritoneal concentrations were higher than 1 microgram/ml (i.e. exceeding the minimal inhibitory concentrations for most of the bacterial species involved in ascitic fluid infections) from the first half-hour after infusion to at least 36 hours.,[Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080483/),[μg] / [ml],1,261548,DB00487,Pefloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB00487,Pefloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB00487,Pefloxacin
,8877537,necrotic pancreatic tissue/serum concentration ratio,"The necrotic pancreatic tissue/serum concentration ratio ranged from 0.9 to 5.1, values depending on tissue sample collection.",Pefloxacin penetration into human necrotic pancreatic tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877537/),,0.9 to 5.1,264355,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],3.54,266150,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],3.43,266151,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.93,266152,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.24,266153,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.79,266154,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.88,266155,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.41,266156,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.91,266157,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.25,266158,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.64,266159,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.29,266160,DB00487,Pefloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.05,266161,DB00487,Pefloxacin
,19086693,elimination-phase disposition half-life (t1/2beta),Pefloxacin exhibits a long elimination-phase disposition half-life (t1/2beta) of 4.89 +/- 1.12 h after IV injection and 5.73 +/- 1.42 h after IM administration.,Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),h,4.89,273061,DB00487,Pefloxacin
,19086693,elimination-phase disposition half-life (t1/2beta),Pefloxacin exhibits a long elimination-phase disposition half-life (t1/2beta) of 4.89 +/- 1.12 h after IV injection and 5.73 +/- 1.42 h after IM administration.,Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),h,5.73,273062,DB00487,Pefloxacin
,19086693,volume of distribution at steady state (Vdss),"The mean volume of distribution at steady state (Vdss) and total body clearance (Cl(tot)) values after IV dosing were 1.18 +/- 0.45 I/kg and 0.21 +/- 0.10 I/kg/h, respectively.",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[i] / [kg],1.18,273063,DB00487,Pefloxacin
,19086693,total body clearance (Cl(tot)),"The mean volume of distribution at steady state (Vdss) and total body clearance (Cl(tot)) values after IV dosing were 1.18 +/- 0.45 I/kg and 0.21 +/- 0.10 I/kg/h, respectively.",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[i] / [h·kg],0.21,273064,DB00487,Pefloxacin
,19086693,peak plasma level (Cmax),The observed peak plasma level (Cmax) of 3.6 +/- 0.1 microg/ml was rapidly attained at 0.75 h (the time of maximum concentration Tmax) after IM administration.,Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[μg] / [ml],3.6,273065,DB00487,Pefloxacin
,19086693,time of maximum concentration Tmax,The observed peak plasma level (Cmax) of 3.6 +/- 0.1 microg/ml was rapidly attained at 0.75 h (the time of maximum concentration Tmax) after IM administration.,Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),h,0.75,273066,DB00487,Pefloxacin
,19086693,areas under the concentration versus time curves (AUCs),"The areas under the concentration versus time curves (AUCs) were 44.18 +/- 9.68 microg x h/ml and 29.42 +/-6.49 microg x h/ml after IV and IM administration, respectively.",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[h·μg] / [ml],44.18,273067,DB00487,Pefloxacin
,19086693,areas under the concentration versus time curves (AUCs),"The areas under the concentration versus time curves (AUCs) were 44.18 +/- 9.68 microg x h/ml and 29.42 +/-6.49 microg x h/ml after IV and IM administration, respectively.",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[h·μg] / [ml],29.42,273068,DB00487,Pefloxacin
,19086693,absolute bioavailability (F%),The absolute bioavailability (F%) obtained after IM administration was 71.59 +/- 12.45%.,Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),%,71.59,273069,DB00487,Pefloxacin
,19086693,peak level,"Milk was penetrated quickly, with a mean peak level of 3.24 +/- 0.17 microg/ml occurring at 1.0 h.",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),[μg] / [ml],3.24,273070,DB00487,Pefloxacin
,19086693,elimination half-life,"The elimination half-life was significantly shorter after IV versus IM administration (4.21 +/- 0.84 h versus 5.32 +/- 0.67 h, respectively).",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),h,4.21,273071,DB00487,Pefloxacin
,19086693,elimination half-life,"The elimination half-life was significantly shorter after IV versus IM administration (4.21 +/- 0.84 h versus 5.32 +/- 0.67 h, respectively).",Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086693/),h,5.32,273072,DB00487,Pefloxacin
